JP Morgan Maintains Overweight on Denali Therapeutics, Raises Price Target to $26

Benzinga · 11/04/2025 15:00
JP Morgan analyst Jessica Fye maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $24 to $26.